How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

8,446 results for

Proton Pump Inhibitor

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Efficacy and safety of hangeshashinto for treatment of GERD refractory to proton pump inhibitors : Usual dose proton pump inhibitors plus hangeshashinto versus double-dose proton pump inhibitors: randomized, multicenter open label exploratory study. (PubMed)

Efficacy and safety of hangeshashinto for treatment of GERD refractory to proton pump inhibitors : Usual dose proton pump inhibitors plus hangeshashinto versus double-dose proton pump inhibitors: randomized, multicenter open label exploratory study. Proton pump inhibitor (PPI)-refractory gastroesophageal reflux disease (GERD) leads to a clinical decline in the quality of life (QOL). Therefore, new treatment options are needed. We performed a multicenter, randomized, parallel-group exploratory

2019 Journal of gastroenterology

2. Proton pump inhibitors: increased mortality

Proton pump inhibitors: increased mortality Prescrire IN ENGLISH - Spotlight ''Proton pump inhibitors: increased mortality'', 1 January 2019 {1} {1} {1} | | > > > Proton pump inhibitors: increased mortality Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Proton pump inhibitors: increased mortality FEATURED REVIEW Proton pump inhibitors (PPIs (...) ) such as omeprazole are used in oesophagitis, gastroesophageal reflux disease and peptic ulcer disease. PPIs have few severe adverse effects in the short term. But this is not the case in the long term. Full review (3 pages) available for download by subscribers. Abstract Proton pump inhibitors (PPIs) are widely used in oesophagitis, gastroesophageal reflux disease and peptic ulcer disease. They provoke few severe adverse effects in the short term, but this is not the case in the long term (infections, fractures

2019 Prescrire

3. Pneumonia caused by proton pump inhibitors (PPI)

Pneumonia caused by proton pump inhibitors (PPI) MED CHECK - TIP December 2017 / Vol.3 No.9 · Page 27 -The Informed Prescriber C N o 9 M ED HECK D e ce m b e r 2 0 1 7 WHO downgrades Tamiflu Suvorexant : A hypnotic causing cataplexy Insomnia, Sleep Duration, Harm of hypnotics PPI causes Pneumonia Editorial WHO downgraded oseltamivir (Tamiflu) New Products Hypnotic (sleeping pill), suvorexant (brand name Belsomra) A substance that causes narcolepsy and cataplexy Teriparatide More harm than (...) benefit: Review Insomnia, Optimal Sleep Duration and Harm of Sleeping pills Pneumonia caused by proton pump inhibitors (PPI) (1) meta-analysis (2) Critical appraisal of a study CONTENTS (December 2017, Vol. 3, No. 9 ) 28 29 34 36 40 42 Volume 3 Page 28 · MED CHECK - TIP December 2017/ Vol.3 No.9 WHO downgrades Tamiflu after reviewing evidence WHO (World Health Organization) reviews their model list of essential medicines every two years. In the revision launched in June 2017, oseltamivir (Tamiflu

2018 Med Check - The Informed Prescriber

4. Proton pump inhibitors

Proton pump inhibitors Top results for proton pump inhibitors - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look (...) like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for proton pump inhibitors The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials

2018 Trip Latest and Greatest

5. Canadian Association of Gastroenterology Statement on the Putative Link Between Proton Pump Inhibitor Treatment and Gastric Cancer after Helicobacter pylori Eradication

Canadian Association of Gastroenterology Statement on the Putative Link Between Proton Pump Inhibitor Treatment and Gastric Cancer after Helicobacter pylori Eradication © The Author(s) 2018. Published by Oxford University Press on behalf of the Canadian Association of Gastroenterology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. 1 Editorial Canadian Association of Gastroenterology Statement on the Putative Link Between Proton Pump Inhibitor T reatment (...) and Gastric Cancer after Helicobacter pylori Eradication A recent paper by Cheung et al. (1) reported that long-term use of proton pump inhibitors (PPIs) was associated with an increased risk of gastric cancer “even after” Helicobacter pylori (H. pylori) eradication. This has created significant concerns among physicians and patients (2). The Canadian Association of Gastroenterology (CAG) has serious reservations about the validity of this study and, hence, considers it important to provide guidance

2019 Canadian Association of Gastroenterology

6. Trends in utilization of proton pump inhibitors in British Columbia

Trends in utilization of proton pump inhibitors in British Columbia Trends in utilization of proton pump inhibitors in British Columbia February - March 2019 Mailing Address: Therapeutics Initiative The University of British Columbia Department of Anesthesiology, Pharmacology & Therapeutics 2176 Health Sciences Mall Vancouver, BC Canada V6T 1Z3 Tel.: 604 822 0700 Fax: 604 822 0701 E-mail: info@ti.ubc.ca www.ti.ubc.ca 118 T he first three Therapeutics Letters focused on com - plaints related (...) to the upper gastrointestinal tract, a common presentation to the primary care physi- cian. 1-3 These Letters reviewed evidence about H 2 -block- ers, eradication of Helicobacter pylori, and drugs used for gastroesophageal reflux. However, they also raised concerns about chronic acid suppression by daily dosing of omeprazole, the first proton pump inhibitor (PPI) on the Canadian market. By 1994 there was already concern that long-term proton pump inhibition could be problem- atic. Since

2019 Therapeutics Letter

7. Proton pump inhibitors for functional dyspepsia. (PubMed)

Proton pump inhibitors for functional dyspepsia. Functional dyspepsia (FD or non-ulcer dyspepsia) is defined as continuous or frequently recurring epigastric pain or discomfort for which no organic cause can be found. Acid suppressive therapy, including proton pump inhibitors (PPIs), has been proposed as a therapeutic option in FD, but its efficacy remains controversial. While PPIs are generally considered safe and well tolerated, they have been associated with adverse events, especially (...) in the long term. For this reason, decisions on whether to initiate or continue PPI therapy should be made based on an appropriate clinical indication. Therefore, we conducted a systematic review to evaluate whether PPI therapy provides symptomatic relief in FD.To determine the efficacy of proton pump inhibitors in the improvement of global symptoms of dyspepsia and quality of life compared to placebo, H2 receptor antagonists or prokinetics, in people with functional dyspepsia.We searched in the following

Full Text available with Trip Pro

2017 Cochrane

8. Deprescribing proton pump inhibitors

Deprescribing proton pump inhibitors 354 Canadian Family Physician • Le Médecin de famille canadien | Vol 63: may • mai 2017 Clinical Practice Guidelines Deprescribing proton pump inhibitors Evidence-based clinical practice guideline Barbara Farrell PharmD ACPR FCSHP Kevin Pottie MD CCFP MClSc FCFP Wade Thompson Taline Boghossian ACPR Lisa Pizzola MSc Farah Joy Rashid ACPR Carlos Rojas-Fernandez PharmD Kate Walsh ACPR Vivian Welch PhD Paul Moayyedi MB ChB PhD MPH Abstract Objective To develop (...) an evidence-based guideline to help clinicians make decisions about when and how to safely taper or stop proton pump inhibitors (PPIs); to focus on the highest level of evidence available and seek input from primary care professionals in the guideline development, review, and endorsement processes. Methods Five health professionals (1 family physician, 3 pharmacists, and 1 gastroenterologist) and 5 nonvoting members comprised the overall team; members disclosed conflicts of interest. The guideline process

2017 CPG Infobase

9. Deprescribing versus continuation of chronic proton pump inhibitor use in adults. (PubMed)

Deprescribing versus continuation of chronic proton pump inhibitor use in adults. Proton pump inhibitors (PPIs) are a class of medications that reduce acid secretion and are used for treating many conditions such as gastroesophageal reflux disease (GERD), dyspepsia, reflux esophagitis, peptic ulcer disease, and hypersecretory conditions (e.g. Zollinger-Ellison syndrome), and as part of the eradication therapy for Helicobacter pylori bacteria. However, approximately 25% to 70% of people

Full Text available with Trip Pro

2017 Cochrane

10. Proton pump inhibitors for functional dyspepsia. (PubMed)

Proton pump inhibitors for functional dyspepsia. Functional dyspepsia (FD or non-ulcer dyspepsia) is defined as continuous or frequently recurring epigastric pain or discomfort for which no organic cause can be found. Acid suppressive therapy, including proton pump inhibitors (PPIs), has been proposed as a therapeutic option in FD, but its efficacy remains controversial. While PPIs are generally considered safe and well tolerated, they have been associated with adverse events, especially (...) in the long term. For this reason, decisions on whether to initiate or continue PPI therapy should be made based on an appropriate clinical indication. Therefore, we conducted a systematic review to evaluate whether PPI therapy provides symptomatic relief in FD.To determine the efficacy of proton pump inhibitors in the improvement of global symptoms of dyspepsia and quality of life compared to placebo, H2 receptor antagonists or prokinetics, in people with functional dyspepsia.We searched in the following

Full Text available with Trip Pro

2017 Cochrane

11. Clopidogrel and Proton Pump Inhibitor Use: A Review of the Evidence on Safety

Clopidogrel and Proton Pump Inhibitor Use: A Review of the Evidence on Safety Clopidogrel and Proton Pump Inhibitor Use: A Review of the Evidence on Safety | CADTH.ca Find the information you need Clopidogrel and Proton Pump Inhibitor Use: A Review of the Evidence on Safety Clopidogrel and Proton Pump Inhibitor Use: A Review of the Evidence on Safety Published on: March 14, 2017 Project Number: RC0874-000 - RD0036-000 Product Line: Research Type: Drug Report Type: Summary with Critical (...) Appraisal Result type: Report Question What are the harms of proton pump inhibitors used concomitantly with clopidogrel for patients requiring antiplatelet therapy following percutaneous coronary intervention? Key Message Although the findings across the studies were mixed, overall, the evidence favours clopidogrel antiplatelet therapy without PPIs. The evidence suggests that there are still some serious safety risks associated with the use of proton pump inhibitors (PPIs) with clopidogrel antiplatelet

2017 Canadian Agency for Drugs and Technologies in Health - Rapid Review

12. Deprescribing Proton Pump Inhibitors

Deprescribing Proton Pump Inhibitors Deprescribing Proton Pump Inhibitors March - April 2018 Mailing Address: Therapeutics Initiative The University of British Columbia Department of Anesthesiology, Pharmacology & Therapeutics 2176 Health Sciences Mall Vancouver, BC Canada V6T 1Z3 Tel.: 604 822 0700 Fax: 604 822 0701 E-mail: info@ti.ubc.ca www.ti.ubc.ca 111 T he first PPI was approved in Canada in 1988. Pronounced and durable reduction of stomach acid production made omeprazole a “blockbuster (...) Inhibitors. Therapeutics Letter. 2016 (Mar-Apr); 99:1-2. 10. Gomm W , von Holt K, Thom F et al. Association of Proton Pump Inhibitors With Risk of Dementia: A Pharmacoepidemiological Claims Data Analysis. JAMA Neurol. 2016;73(4):410-6. DOI:10.1001/jamaneurol.2015.4791 11. Filion KB, Chateau D, Targownik LE et al. Proton pump inhibitors and the risk of hospitalization for community-acquired pneumonia: replicated cohort studies with meta-analysis. Gut 2014; 63(4):552-558. DOI:10.1136/gutjnl-2013-304738 12

2018 Therapeutics Letter

13. Core IM: 5 pearls on proton pump inhibitors

Core IM: 5 pearls on proton pump inhibitors Core IM: 5 Pearls on PPIs – Clinical Correlations Search Core IM: 5 Pearls on PPIs August 29, 2018 15 min read Podcast: | Subscribe: | By Cary Blum MD, Marty Fried MD and Shreya P. Trivedi MD || Illustration by Michael Shen MD. Quiz yourself on the 5 Pearls we will be covering: What are associated adverse effects for patients are on long-term PPIs? (2:02) What are some strategies to get your patient off PPIs? (10:57) How do histamine-2 (H2) receptor (...) have a great graphic of the physiology that might be helpful to follow along with on any of our social media C: Great. So remember that gastric acid is secreted by what cells? M: Umm… Stomach cells? C: Ummm, yes… but more specifically [pause for beat] parietal cells [M: ahhhhh]. They have the hydrogen-potassium ATPase – otherwise known as… S: the proton pump! C: That’s right! The infamous proton pump – purveyor of agida, head honcho of heartburn, the regal ruler of the reflux regime, the- you guys

2018 Clinical Correlations

14. General medicine: Proton pump inhibitor therapy after Helicobacter pylori eradication may increase the risk of gastric cancer

General medicine: Proton pump inhibitor therapy after Helicobacter pylori eradication may increase the risk of gastric cancer Proton pump inhibitor therapy after Helicobacter pylori eradication may increase the risk of gastric cancer | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Proton pump inhibitor therapy after Helicobacter pylori eradication may increase the risk of gastric cancer Article Text Commentary General medicine

2018 Evidence-Based Medicine (Requires free registration)

15. [Optimal long-term use of proton pump inhibitors]

[Optimal long-term use of proton pump inhibitors] Usage optimal à long terme des inhibiteurs de la pompe à protons [Optimal long-term use of proton pump inhibitors] Usage optimal à long terme des inhibiteurs de la pompe à protons [Optimal long-term use of proton pump inhibitors] Tremblay E, Tardif M Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database (...) . Citation Tremblay E, Tardif M. Usage optimal à long terme des inhibiteurs de la pompe à protons. [Optimal long-term use of proton pump inhibitors] Quebec: Institut national d'excellence en sante et en services sociaux (INESSS). 2016 Authors' conclusions Upon gathering information from good clinical practice recommendations and during multiple consultations, INESSS made the following observations: • Prescribing PPIs is unwarranted in many cases. • It will take more than clinical tools and training

2017 Health Technology Assessment (HTA) Database.

16. Risk of small intestinal bacterial overgrowth in patients receiving proton pump inhibitors versus proton pump inhibitors plus prokinetics (PubMed)

Risk of small intestinal bacterial overgrowth in patients receiving proton pump inhibitors versus proton pump inhibitors plus prokinetics Intestinal dysmotility is considered a risk factor for small intestinal bacterial overgrowth (SIBO). Prokinetics improve intestinal motility and are often prescribed with proton pump inhibitors (PPIs) in patients with gastroesophageal reflux disease (GERD) and/or functional dyspepsia. The present study aimed to evaluate the prevalence of SIBO and the orocecal

Full Text available with Trip Pro

2018 JGH Open: An Open Access Journal of Gastroenterology and Hepatology

17. Pre-Endoscopic Intravenous Proton Pump Inhibitors for Emergency Department Patients with Upper Gastrointestinal Bleeds: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines

Pre-Endoscopic Intravenous Proton Pump Inhibitors for Emergency Department Patients with Upper Gastrointestinal Bleeds: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines Pre-Endoscopic Intravenous Proton Pump Inhibitors for Emergency Department Patients with Upper Gastrointestinal Bleeds: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines | CADTH.ca Find the information you need Pre-Endoscopic Intravenous Proton Pump Inhibitors for Emergency Department (...) Patients with Upper Gastrointestinal Bleeds: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines Pre-Endoscopic Intravenous Proton Pump Inhibitors for Emergency Department Patients with Upper Gastrointestinal Bleeds: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines Published on: February 5, 2016 Project Number: RC0740-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness

2016 Canadian Agency for Drugs and Technologies in Health - Rapid Review

18. Proton Pump Inhibitors (PPIs): Is Perpetual Prescribing Inevitable?

Proton Pump Inhibitors (PPIs): Is Perpetual Prescribing Inevitable? Tools for Practice is proudly sponsored by the Alberta College of Family Physicians (ACFP). ACFP is a provincial, professional voluntary organization, representing more than 4,500 family physicians, family medicine residents, and medical students in Alberta. Established over sixty years ago, the ACFP strives for excellence in family practice through advocacy, continuing medical education and primary care research. www.acfp.ca (...) June 26, 2017 Proton Pump Inhibitors (PPIs): Is Perpetual Prescribing Inevitable? Clinical Question: How successful are attempts to stop PPIs and how can clinicians improve chances of success? Bottom Line: Using a range of deprescribing strategies, about 25% of patients with gastroesophageal reflux disease (GERD) or dyspepsia can stop PPI use and another 30-50% can decrease their dose. Older patients and those who taper appear more successful in stopping PPIs. Evidence: • Clustered randomized

2017 Tools for Practice

19. A systematic review of the comparative effectiveness of proton pump inhibitors for the treatment of adult patients with gastroesophageal reflux disease or peptic ulcer disease

A systematic review of the comparative effectiveness of proton pump inhibitors for the treatment of adult patients with gastroesophageal reflux disease or peptic ulcer disease A systematic review of the comparative effectiveness of proton pump inhibitors for the treatment of adult patients with gastroesophageal reflux disease or peptic ulcer disease | Therapeutics Initiative Independent Healthcare Evidence > > A systematic review of the comparative effectiveness of proton pump inhibitors (...) for the treatment of adult patients with gastroesophageal reflux disease or peptic ulcer disease This was produced by the Drug Assessment Working Group of the Therapeutics Initiative at the request of the Pharmaceutical Services Division (PSD) of the British Columbia Ministry of Health as part of the Drug Effectiveness Review Project (DERP), a class review of proton pump inhibitors (PPIs) for the treatment of adult patients with symptomatic GERD or PUD. Research questions Four research questions were

2016 Therapeutics Letter

20. Comparative effectiveness of proton pump inhibitors

Comparative effectiveness of proton pump inhibitors March - April 2016 99 © Mailing Address: Therapeutics Initiative The University of British Columbia Department of Anesthesiology, Pharmacology & Therapeutics 2176 Health Sciences Mall Vancouver, BC Canada V6T 1Z3 Comparative effectiveness of proton pump inhibitors Comparative trials of PPIs in adult patients with symptomatic PUD Based on 6 RCTs in 1753 patients, esomeprazole was not significantly different from other PPIs for most outcome (...) proton pump inhibitors (PPIs). 1-6 These drugs work by irreversibly inhibiting gastric H+K+ ATPase (the proton pump) in the stomach. They inhibit both basal and stimulated acid secretion and are used in a number of clinical set- tings: gastroesophageal reflux disease (GERD), reflux esophagitis, peptic ulcer disease (PUD), and symptoms associated with stomach acid such as heartburn and acid indigestion. Are there any important differences between the different drugs in the class? We have conducted two

2016 Therapeutics Letter

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>